LAUSANNE, Switzerland – Today, Timeline®, a trailblazer in the field of longevity biotechnology, proudly announced the conclusion of its pivotal MitoImmune clinical trial. This study marks a significant advancement in understanding immune aging through the use of Mitopure™, Timeline’s proprietary form of Urolithin A.
Chris Rinsch, PhD, Co-Founder and President of Timeline, expressed enthusiasm about the study’s success: “Our mission has always been to pioneer research that unlocks clinically proven interventions to help people stay healthier for longer. These results open a totally new approach to directly impact our immune cells and help restore their functionality during aging.”
The MitoImmune study, a randomized, placebo-controlled trial, was conducted in collaboration with leading institutions including the Georg-Speyer-Haus Institute for Tumor and Experimental Therapy and the Buck Institute for Research on Aging in California. Over a period of four weeks, the trial engaged 50 middle-aged participants, achieving its primary endpoints: an increase in youthful naive CD8 T-cells and improved mitochondrial activity within these cells. Additional outcomes included reduced inflammation markers associated with aging.
Building on these encouraging results, Timeline is embarking on two more investigator-led clinical trials. One study, in partnership with the National Institute of Aging, will examine Mitopure’s effects on glucose metabolism in overweight middle-aged adults. Another, with the National Institute of Cancer, will explore its potential to manage oxidative stress in prostate cancer patients.
For further details on Timeline’s research initiatives and Mitopure’s role in promoting healthier, longer lives, please visit Timeline Studies.
Credit Note
This article has been adapted from the original press release published on Business Wire. The original press release, titled “Longevity Biotech, Timeline, Leads the Way in Healthy Aging Research with Groundbreaking Clinical Studies,” can be found here.
